# Lexeo Therapeutics, Inc.: overview LXEO · Nasdaq · CIK 1907108 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lxeo.md) · [Financials](/companies/lxeo/financials.md) · [Filings](/companies/lxeo/filings.md) · [Insiders](/companies/lxeo/insiders.md) Latest reported revenue: [$0](/filings/0000950170-24-028941.md) for period not labelled, three months to 2022-12-31, from the 10-K filed Mar 11, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-24-028941). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.89)](/filings/0001193125-25-265757.md) | not reported | [(0.99)](/filings/0001193125-26-215678.md) | [(0.60)](/filings/0001193125-26-345724.md) | [(0.33)](/filings/0001193125-25-265757.md) | not reported | [(0.25)](/filings/0001193125-26-215678.md) | [(0.30)](/filings/0001193125-26-345724.md) | | Free cash flow | $m | [(17.9) d](/filings/0001193125-25-265757.md) | [(28.3) d](/filings/0001193125-26-132085.md) | not reported | not reported | [(29.8) d](/filings/0001193125-25-265757.md) | [(20.1) d](/filings/0001193125-26-132085.md) | [(21.2)](/filings/0001193125-26-215678.md) | [(17.6) d](/filings/0001193125-26-345724.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [0.7](/filings/0000950170-24-028941.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | [(9252.1%)](/filings/0000950170-24-028941.md) | not reported | not reported | not reported | | Net margin | % | [(9063.8%)](/filings/0000950170-24-028941.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(36.36)](/filings/0000950170-24-028941.md) | [(12.40)](/filings/0000950170-25-043486.md) | [(3.09)](/filings/0001193125-26-132085.md) | [(1.86)](/filings/0001193125-26-132085.md) | | Free cash flow | $m | [(55.2)](/filings/0000950170-24-028941.md) | [(59.6)](/filings/0000950170-25-043486.md) | [(81.6)](/filings/0001193125-26-132085.md) | [(99.0)](/filings/0001193125-26-132085.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lxeo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $29.7m | 6,384,200 | | Added +5,134,200 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $28.5m | 4,976,429 | | Not compared | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $27.0m | 5,807,611 | | Added +757,400 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $26.7m | 5,739,455 | | Added +628,584 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $23.3m | 5,000,000 | | Unchanged | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $22.5m | 4,824,725 | | Added +400,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $20.3m | 4,354,757 | | Added +786,515 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $20.1m | 4,320,000 | | Reduced −155,000 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $19.4m | 4,175,382 | | Reduced −2,008,752 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $18.4m | 3,954,691 | | Not compared | ## Recent filings [All 352 filings](/companies/lxeo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 16:20 ET | [8-K](/filings/0001193125-26-407555.md) | 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-407555 | | 2026-09-22 | 07:08 ET | [8-K](/filings/0001193125-26-397221.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-397221 | | 2026-08-12 | 07:04 ET | [10-Q](/filings/0001193125-26-345724.md) | Quarterly report, period 2026-06-30 | 0001193125-26-345724 | | 2026-08-12 | 07:02 ET | [8-K](/filings/0001193125-26-345722.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-345722 | | 2026-06-29 | 17:06 ET | [8-K](/filings/0001193125-26-288703.md) | 5.07 Shareholder vote results | 0001193125-26-288703 | | 2026-06-15 | 07:05 ET | [8-K](/filings/0001193125-26-270275.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270275 | | 2026-05-11 | 07:05 ET | [10-Q](/filings/0001193125-26-215678.md) | Quarterly report, period 2026-03-31 | 0001193125-26-215678 | | 2026-05-11 | 07:03 ET | [8-K](/filings/0001193125-26-215674.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-215674 | | 2026-04-30 | 07:01 ET | [DEF 14A](/filings/0001193125-26-193930.md) | Proxy statement, period 2025-12-31 | 0001193125-26-193930 | | 2026-04-30 | 07:00 ET | [8-K](/filings/0001193125-26-193927.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-193927 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-132085.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1907108 - Tickers: LXEO - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:31 ET. No prices; not investment advice.